CSL is committed to ensuring that pricing for our products is done in a responsible manner both for patients and investors. Pricing is a key factor amongst a number of other considerations that can significantly impact patient access in both developed and developing markets. At CSL, we seek input from governments, patient groups and other healthcare stakeholders to address access issues and to evaluate pricing of therapies areas across all business units. Prices of medicines reflect the clinical value to patients, communities and governments and provide an economic basis for future investment into the development of new therapies. Demonstrating that value by generating data to illustrate long-term health and economic value is an important element to the pricing equation. This continues to be a focus for CSL.
In addition, CSL's policy support via grants and collaborations seek to facilitate patient advocacy for appropriate access to therapies and combatting of undue burdens on patient cost-sharing, such as specialty tiers with very high co-insurance rates, overly restrictive access formularies that inhibit patient care, and delays in or complete lack of approvals of payment for new treatments.
In 2015/16, CSL provided a number of therapies to 38 low-to-middle-income countries (representing 37% of all low-to-middle- income countries as classified by the World Bank at December 2015). Access to these therapies is either through a local distributor in response to a competitive tender or via direct arrangement with governments or non-government organisations (NGOs). In addition, across our key therapy areas, CSL's long-standing partnerships with the World Federation of Hemophilia (WFH) and the Jeffrey Modell Foundation (JMF), among others, help to improve access to our therapies in developing countries.
CSL marked World Hemophilia Day in April 2016 by contributing more than 1.5 million international units (IUs) of treatments for haemophilia A and/or von Willebrand disease. The contribution is a part of CSL Behring’s three-year promise to provide more than 10 million IUs of specialty biotherapeutics to the World Federation of Hemophilia (WFH) to treat haemophilia in the developing world. In 2015, CSL Behring’s product donations to the WFH supported haemophilia patients in Ghana, Honduras, Jordan, Myanmar, Nepal, Nigeria, Pakistan, Paraguay, Philippines, Rwanda, Thailand and the Ukraine.
CSL is committed to supporting the Jeffrey Modell Foundation (JMF)’s mission of hope, advocacy and action by vigorously supporting physicians, researchers and the ever-expanding global patient community – directing its efforts towards early diagnosis, meaningful treatments and equal access to care for patients with primary immunodeficiency diseases. CSL has been a long-term contributor to the JMF
and, in addition to other activities, funds 13 Jeffrey Modell Centres (JMC) around the world, including two in low-to-middle-income counties. We continually explore opportunities to establish new JMCs with the JMF and are currently evaluating sites in Africa.
CSL also supports Alpha1-Global, which is a non-profit organisation whose mission includes spreading awareness and increasing diagnosis of Alpha-1 antitrypsin deficiency (Alpha-1) throughout the world, including in low-to-middle-income countries. They have held meetings in Latin America and Lebanon, for example, to further that mission. Alpha-1 is a rare genetic condition which may result in serious lung disease in adults and/or liver disease in children and adults.
In addition, CSL is supporting the Hereditary Angioedema International (HAEi) patient organisation, which is dedicated to advancing awareness, diagnosis and treatment for hereditary angioedema around the world.